Details

Autor(en) / Beteiligte

• Jung, Sung-Hoon
• Kwon, Seong Young
• Min, Jung-Joon
• Bom, Hee-Seung
• Ahn, Seo-Yeon
• Jung, Seung-Yeon
• Lee, Seung-Shin
• Park, Moo-Rim
• Yang, Deok-Hwan
• Ahn, Jae-Sook
• Kim, Hyeoung-Joon
• Lee, Je-Jung

Titel

18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System

Ist Teil von

• European journal of nuclear medicine and molecular imaging, 2019, Vol.46 (1), p.107-115

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2019

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• Purpose This study evaluated the prognostic role of 18 F-FDG PET/CT at baseline in patients with newly diagnosed multiple myeloa (MM) and evaluated the prognostic relevance of 18 F-FDG PET/CT for each stage according to the Revised International Staging System (R-ISS). Method We retrospectively analyzed the records of 167 patients with newly diagnosed MM. 18 F-FDG PET/CT was performed prior to induction therapy in patients with newly diagnosed MM. Results In the total cohort, the presence of more than three hypermetabolic focal lesions (FLs) or extramedullary disease (EMD) on baseline PET/CT was associated with significantly inferior progression-free survival (PFS) and overall survival (OS) than other patients. Because most patients (91%) with EMD had more than three FLs, PET/CT positivity was defined as the presence of more than three FLs or the presence of EMD. In multivariate analyses, PET/CT positivity was an independent predictor of PFS and OS in all patients. Fifty-five patients (46.1%) with R-ISS II were PET/CT-positive at baseline and had significantly shorter PFS and OS. PET/CT positivity was also correlated with poor PFS and OS in patients with R-ISS III. Conclusion 18 F-FDG PET/CT was an independent predictor of survival outcomes in patients with newly diagnosed MM. In addition, performing 18 F- FDG PET/CT at diagnosis may be useful for determining the survival outcomes of MM patients with R-ISS II and III.